Last reviewed · How we verify
Ixekizumab Auto-Injector
Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.
Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Ixekizumab Auto-Injector |
|---|---|
| Also known as | LY2439821 |
| Sponsor | Eli Lilly and Company |
| Drug class | IL-17A inhibitor (monoclonal antibody) |
| Target | IL-17A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-17A is a pro-inflammatory cytokine produced by T cells that plays a central role in the pathogenesis of autoimmune and inflammatory conditions. By blocking IL-17A, ixekizumab reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing the inflammatory cascade. This mechanism is particularly effective in conditions driven by Th17 cell-mediated immunity, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Candida infections (oral/esophageal)
- Headache
- Nausea
Key clinical trials
- Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris (EARLY_PHASE1)
- Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |